Athira Pharma, Inc.

NasdaqGS:ATHA Voorraadrapport

Marktkapitalisatie: US$23.3m

Athira Pharma Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat Athira Pharma de winst en omzet met respectievelijk 21.8% en 56.3% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 31.7% per jaar.

Belangrijke informatie

21.8%

Groei van de winst

31.7%

Groei van de winst per aandeel

Pharmaceuticals winstgroei23.6%
Inkomstengroei56.3%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt19 Sep 2024

Recente toekomstige groei-updates

Recent updates

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Feb 16
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Nov 02
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

May 29
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Jan 04
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Oct 17

Athira Pharma GAAP EPS of -$0.65

Aug 15

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Aug 09
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Jun 22

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

May 08
Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Jan 11
We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Athira Pharma: What, Exactly, Did The CEO Do?

Jun 29

Athira Pharma falls after the decision to place CEO on temporary leave

Jun 17

Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy

Jun 07

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

May 24
We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Feb 08
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach

Jan 11

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Dec 18
Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Athira Pharma nabs research grant of $15M from NIH

Dec 08

Athira Pharma reports Q3 results

Nov 12

Winst- en omzetgroeiprognoses

NasdaqGS:ATHA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20264-52-149N/A3
12/31/2025N/A-69-132N/A4
12/31/2024N/A-100-96N/A5
6/30/2024N/A-113-98-98N/A
3/31/2024N/A-116-100-100N/A
12/31/2023N/A-118-101-101N/A
9/30/2023N/A-121-90-90N/A
6/30/2023N/A-108-88-88N/A
3/31/2023N/A-102-83-82N/A
12/31/2022N/A-96-74-72N/A
9/30/2022N/A-82-77-75N/A
6/30/2022N/A-77-66-64N/A
3/31/2022N/A-67-54-52N/A
12/31/2021N/A-55-45-43N/A
9/30/2021N/A-46-38-36N/A
6/30/2021N/A-39-37-35N/A
3/31/2021N/A-27-33-30N/A
12/31/2020N/A-20-26-24N/A
9/30/2020N/A-13-15-14N/A
6/30/2020N/A-6-6-6N/A
3/31/2020N/A-6-4-4N/A
12/31/2019N/A-5-4-4N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat ATHA de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat ATHA de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat ATHA de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat ATHA volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat ATHA volgend jaar geen omzet zal hebben.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ATHA naar verwachting over 3 jaar hoog zal zijn


Ontdek groeibedrijven